NETSPOT is all set to become a preferred diagnostic drug kit for NET patients I believe that solid ramp up of NETSPOT in USA can prove to be a significant growth opportunity for the company in 2017. In this article, I will present my rationale for considering Advanced Accelerator Applications as a solid buy opportunity in 2017. With Advanced Accelerator Applications launching multiple products across geographies and securing reimbursement, these revenue numbers are expected to rise significantly in 20. The company reported a compounded average growth rate of 29.5% in its revenues from 2012 to 2015. In 2015, Advanced Accelerator Applications posted revenues close to €88.6 million. The company is also moving closer to launching its first MNM therapy, Lutathera, for neuroendocrine tumor or NET patients both in USA and European Union. This radiopharmaceutical company currently markets seven diagnostic products in the European market and recently launched one of its products in USA.īesides these commercialized diagnostic drug kits, Advanced Accelerator Applications also boasts of six investigational candidates in its research pipeline. Advanced Accelerator Applications offers positron emission tomography or PET and single-photon emission computed tomography or SPECT products which are used to diagnose conditions in areas such as neurology, oncology, cardiology, infectious diseases, and inflammation. Since last few years, the company has been steadily increasing its presence in USA. Advanced Accelerator Applications ( NASDAQ: AAAP) is a leader in the European molecular nuclear medicine or MNM segment.
0 Comments
Leave a Reply. |